AKT1 and cancer: They reported that luteolin significantly reduced stem-like properties of paclitaxel resistant cancer cells by downregulating SOX2 protein expression and could prevent the PI3K/AKT pathway to reduce AKT (S473) and UBR5 expression, which could promote SOX2 degradation [107].